1Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
2Division of Health Care Policy and Research, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
Am J Trop Med Hyg. 2021 Jan 4;104(3):1000-1002. doi: 10.4269/ajtmh.20-1187.
The WHO recommends single low-dose (SLD) primaquine as a gametocytocide to reduce Plasmodium falciparum transmission in areas of low transmission. Despite this recommendation, uptake of SLD primaquine has been low because of concerns of glucose-6-phosphate dehydrogenase (G6PD) deficiency. Individuals with G6PD deficiency can experience hemolysis when exposed to primaquine. In Southern Province, Zambia, malaria transmission has declined significantly over the past decade. Single low-dose primaquine may be an effective tool, but there is limited information on G6PD deficiency. We screened 137 residents in Macha, Southern Province, Zambia, and the prevalence of G6PD (A-) was 15%. We also revisited data collected from 2008 to 2013 in the same area and found the highest gametocyte burden among those aged 5-15 years. The findings from this study suggest that SLD primaquine targeted to school-aged children may be an effective tool to help achieve malaria elimination in southern Zambia.
世界卫生组织推荐使用单一低剂量(SLD)伯氨喹啉作为配子体杀灭剂,以减少低传播地区的恶性疟原虫传播。尽管有此推荐,但由于担心葡萄糖-6-磷酸脱氢酶(G6PD)缺乏症,SLD 伯氨喹啉的使用率一直很低。G6PD 缺乏症患者在接触伯氨喹啉时可能会发生溶血。在赞比亚南部省,疟疾传播在过去十年中显著下降。单一低剂量伯氨喹啉可能是一种有效的工具,但关于 G6PD 缺乏症的信息有限。我们对赞比亚南部马查的 137 名居民进行了筛查,发现 G6PD(A-)的患病率为 15%。我们还重新审视了 2008 年至 2013 年在同一地区收集的数据,发现 5-15 岁年龄组的配子体负担最高。这项研究的结果表明,针对学龄儿童的 SLD 伯氨喹啉可能是在赞比亚南部实现消除疟疾的有效工具。